Conducting clinical trials in the age of COVID-19 has become more challenging than ever and it is evident that innovative and adaptive approaches to Sponsor/site alliance strategies are key to maintaining business continuity in the changing landscape. But how are those strategies developed? What are the key drivers that motivate Sponsors and sites to build alliances? And how can alliances be leveraged to build pivot strategies in response to portfolio changes or other unexpected events like COVID-19?
In this virtual on-demand discussion with roundtable interactive Q&A on Roche/Genentech's framework for developing strategic clinical site alliance models, participants will gain insight and understanding into:
Senior Alliance & Partnerships Leader | Clinical Operations
Genentech Research and Early Development
As a Senior Alliance and Partnership Leader in Genentech's Early Clinical Development group, Dimitri leads the development and execution of alliance relationships with clinical sites to support Genentech's early development pipeline. In the role, he collaborates with clinical operations, clinical science and other key stakeholders at the company as well as investigators, study coordinators, and research scientists at sites to come up with strategies that enable innovative approaches to study design, seamless study execution, and establishment of long-term relationships. Before joining the Alliance and Partnership team, Dimitri worked as a Biomarker Operations Leader in Genentech's Development Sciences group, overseeing the successful execution of exploratory biomarker strategies across many therapeutic areas for Genentech early development programs. He has over 15 years of industry experience spanning business development and alliance management, project management, biostatistics, exposure and risk assessment, epidemiology, toxicology, lab quality control/quality assurance, and immunology lab research.
Jessica Piggee, MPH
Senior Alliance and Partnership Leader
Genentech, gRED Early Clinical Development
Jessica is a Senior Alliance and Partnership Leader in the gRED Early Clinical Development team at Genentech. Jessica has been in this role with Genentech since October 2019. In this role, she is accountable for defining, developing, and implementing site engagement strategies to further enhance delivery of the gRED portfolio. This role draws on her experience that spans a range of strategic disciplines including innovation and strategic planning, partnership and collaboration, and site operational efficiencies and implementation.
Prior to joining Genentech, Jessica was with the Sarah Cannon Research Institute for over 12 years in multiple roles focused on supporting oncology clinical trials at their network sites and building relationships with sponsor and CRO partners. She also spent 5 years at Vanderbilt University Medical Center building and managing their HEM/BMT clinical trial program.